Research Article

Factors Affecting the Self-Isolation Monitoring Program for COVID-19 Patients at the Universitas Indonesia Hospital

Rakhmad Hidayat,1,2,3 Zlatikha Djuliannisaa,1,2 Alyssa Putri Mustika,1,2,3 Gemia Clarisa Fathi,3 Muhammad Hafiz Aini,3 Wahyu Ika Wardani,3 Assifa Swasti Anindita,3 Siti Azizah,3 Astuti Giantini,1,2,3 and Muhammad Arza Putra1,2,3

1Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
2Cipto Mangunkusumo Hospital, Jakarta, Indonesia
3Universitas Indonesia Hospital, Depok, Indonesia

Correspondence should be addressed to Rakhmad Hidayat; rhidayat.md@gmail.com

Received 2 May 2022; Revised 5 July 2022; Accepted 4 August 2022; Published 24 August 2022

1.Introduction

From June 28, 2021, to July 30, 2021, the number of confirmed cases of COVID-19 in Indonesia experienced a twofold increase, with the number of deaths increasing by nearly 50%. [1] This occurred during the delta variant outbreak, and based on government data, the delta variant comprised 98.9% of COVID-19 cases. [2] At this time, there was a notable increase in the rate of emergencies and utilization of hospital resources. Data from a hospital in Indonesia noted that there were 63 deaths in one day, and 33 deaths occurred once the central oxygen supply was exhausted. According to the Indonesian Doctors Association, more than 400 doctors have died in Indonesia since the pandemic started. [3] The number of cases in Jakarta increased by 35% during this period, with the highest number of patients on self-isolation reaching 88,295. [4, 5] Accordingly, many people were infected with COVID-19 and underwent self-isolation. This required attention and supervision from health workers at the hospital in order to achieve effective self-isolation.

Under supervision, health workers must assess a patient’s overall condition. To optimize observation and prevent patient deterioration, the symptoms, physical examination, and support that can affect the outcome of COVID-19 patients must be known. Thus, immediate treatment can be performed on patients with deterioration, given that the bed occupancy rate in Jakarta once reached 100%, which made it challenging for patients with deteriorating conditions to receive hospital treatment. [6–8] A similar incident also occurred in
Singapore, where 89% of hospital beds for isolation patients were occupied, and patients requiring further treatment experienced difficulties. Therefore, this study was conducted to identify factors that affected the outcomes of patients on COVID-19 self-isolation.

The Universitas Indonesia Hospital created an independent isolation monitoring program (One Stop Service (OSS)), where patients came in private vehicles and underwent symptom assessment, vital sign evaluation, blood tests, thoracic radiography, drug administration, and monitoring of the patient’s clinical condition over two weeks. This study was conducted to determine the effectiveness of the self-isolation monitoring performed by hospitals and the factors that affected the deterioration of patients on self-isolation.

2. Materials and Methods

This cross-sectional study used secondary data (from the electronic medical records) of patients who participated in the Universitas Indonesia Hospital self-isolation observation program from June 28, 2021, to July 30, 2021. The study included patients on COVID-19 self-isolation. At this stage, there were 206 patients. We excluded COVID-19 patients who were lost to follow-up or did not complete the self-isolation program, which finally resulted in 197 patients. Data collection consisted of the patient’s symptoms, physical examination, laboratory findings, radiology results, and patient outcomes. The data were analyzed by evaluating the association between the risk factors and the effects of the self-isolation monitoring program. Descriptive statistics were used in the study. The chi-squared test was used to determine the direct effect of risk factors, with patient outcomes as the dependent variable. We use SPSS 26 for the statistic process, and we consider significant result if p-value <0.05.

This research was approved by The Ethics Committee of Universitas Indonesia Hospital, approval number S-009/KETLIT/RSUI/II/2022 with protocol number 2021-09-098. This research also followed the Declaration of Helsinki guidelines. The Ethics Committee of Universitas Indonesia Hospital granted a waiver of informed consent due to retrospective data collection, and guaranteed the privacy of the participant in this research was maintained with confidentiality.

3. Results

There were more female patients (56.35%) than male patients (43.65%) (Table 1) among the 197 patients. Most patients were over 45 years of age (48.73%). More patients were clinically asymptomatic or mildly symptomatic (65.48%) than moderately or severely symptomatic (34.51%).

The patients’ characteristics are presented in Table 2 and included sex, age <45 years and >45 years, and the clinical severity of the COVID-19 disease. The patients were also divided into asymptomatic patients and those with mild, moderate, and severe symptoms. The patients were also monitored to determine whether they had completed the OSS follow-up program conducted by the Universitas Indonesia Hospital. We assessed the administration of antivirals and antibiotics and the history of vaccination before the patient was infected with COVID-19. The degree of symptom severity significantly affected patient outcomes. The use of antibiotics also significantly increased the risk of unimproved patient outcomes (p <0.005).

Twelve main symptoms were assessed in patients undergoing COVID-19 self-isolation, including fever, cough, runny nose, shortness of breath, fatigue, myalgia, anosmia, headache, sore throat, nausea and vomiting, diarrhea, and ageusia (Table 3). Shortness of breath had the most significant effect on outcomes among the patients (p = 0.001).

Table 4 shows several laboratory tests performed on the patients as part of the Universitas Indonesia Hospital self-isolation monitoring program, including C-reactive protein (CRP), erythrocyte sedimentation rate, alanine aminotransferase (ALT), hemoglobin, hematocrit, and neutrophil-lymphocyte ratio (NLR). However, some patients did not undergo these examinations, and were included in another category. The analysis found that a normal ALT level was a significant predictor of improved COVID-19 outcomes among self-isolated patients (p <0.05).

Table 5 shows the results of the radiological examinations. The patients were divided into several categories based on the presence of abnormalities in the thoracic radiography results. Radiological test results were not significant determinants of outcomes among patients undergoing COVID-19 self-isolation. No significant trend showed that patients without abnormalities had a better improvement.

Table 6 shows that physical examinations were performed when the patient first visited to participate in the self-isolation program. Examinations included blood pressure, oxygen saturation, temperature, and pulse. However, some patients did not come in person; therefore, some examination data could not be obtained, and they were excluded from the total sample for this category. The data were not well distributed among all physical examinations; therefore, no significant parameter was found to determine patient outcomes. However, patients who had poor initial saturation had the 3.403-fold potential to experience deterioration. A crucial
### Table 2: Clinical data of COVID-19 self-isolation patients.

| Outcome          | Better | Worse | p value | OR   | CI      |
|------------------|--------|-------|---------|------|---------|
| **Gender**       |        |       |         |      |         |
| Male             | 102 (51.8%) | 9 (4.6%) | 0.994* | 1.004 | 0.358–2.814 |
| Female           | 79 (40.1%)  | 7 (3.6%)  |       |      |         |
| **Age**          |        |       |         |      |         |
| <45 years old    | 96 (48.7%)  | 5 (2.5%)  | 0.095* | 2.485 | 0.830–7.440 |
| >45 years old    | 85 (43.1%)  | 11 (5.6%) |       |      |         |
| **Clinical degree** |      |       |         |      |         |
| Asymptomatic-mild | 124 (62.9%) | 4 (2.0%)  | 0.000* | 6.526 | 2.017–21.117 |
| Moderate-severe  | 57 (28.9%)  | 12 (6.1%) |       |      |         |
| **Vaccine**      |        |       |         |      |         |
| Yes              | 132 (67.0%) | 13 (6.6%) | 0.469* | 0.622 | 0.170–2.275 |
| No               | 49 (24.9%)  | 3 (1.5%)  |       |      |         |
| **Antiviral**    |        |       |         |      |         |
| Yes              | 111 (56.3%) | 13 (6.6%) | 0.114* | 0.366 | 0.101–1.330 |
| No               | 70 (35.5%)  | 3 (1.5%)  |       |      |         |
| **Antibiotic**   |        |       |         |      |         |
| Yes              | 123 (62.4%) | 15 (7.6%) | 0.031* | 0.141 | 0.018–1.096 |
| No               | 58 (29.4%)  | 1 (0.5%)  |       |      |         |

* Chi-square.

### Table 3: Main symptoms and outcomes of COVID-19 self-isolation patients.

| Outcome          | Better | Worse | p value | OR   | CI      |
|------------------|--------|-------|---------|------|---------|
| **Fever**        |        |       |         |      |         |
| Yes              | 78 (39.60%) | 8 (4.10%)  | 0.593* | 0.757 | 0.272–2.107 |
| No               | 103 (52.30%) | 8 (4.10%)  |       |      |         |
| **Cough**        |        |       |         |      |         |
| Yes              | 146 (74.10%) | 15 (7.60%) | 0.194* | 0.278 | 0.036–2.177 |
| No               | 35 (17.80%)  | 1 (0.50%)  |       |      |         |
| **Runny nose**   |        |       |         |      |         |
| Yes              | 54 (27.40%)  | 4 (2.00%)  | 0.684* | 1.276 | 0.394–4.133 |
| No               | 127 (64.50%) | 12 (6.10%) |       |      |         |
| **Shortness of breath** |    |       |         |      |         |
| Yes              | 22 (11.20%)  | 7 (3.60%)  | 0.001* | 0.178 | 0.060–0.526 |
| No               | 159 (80.70%) | 9 (4.60%)  |       |      |         |
| **Fatigue**      |        |       |         |      |         |
| Yes              | 8 (4.10%)  | 2 (1.00%)  | 0.158* | 0.324 | 0.063–1.673 |
| No               | 173 (87.80%) | 14 (7.10%) |       |      |         |
| **Anosmia**      |        |       |         |      |         |
| Yes              | 65 (33.00%)  | 4 (2.00%)  | 0.38*  | 1.681 | 0.521–5.425 |
| No               | 116 (58.90%) | 12 (6.10%) |       |      |         |
| **Headache**     |        |       |         |      |         |
| Yes              | 45 (22.80%)  | 2 (1.00%)  | 0.266* | 2.316 | 0.507–10.584 |
| No               | 136 (69.00%) | 14 (7.10%) |       |      |         |
| **Sore throat**  |        |       |         |      |         |
| Yes              | 13 (6.60%)  | 1 (0.50%)  | 0.889* | 1.161 | 0.142–9.492 |
| No               | 168 (85.30%) | 15 (7.60%) |       |      |         |
| **Nausea and vomiting** |    |       |         |      |         |
| Yes              | 39 (19.80%)  | 6 (3.00%)  | 0.145* | 0.458 | 0.157–1.338 |
| No               | 142 (72.10%) | 10 (5.10%) |       |      |         |
| **Diarrhoea**    |        |       |         |      |         |
| Yes              | 24 (12.20%)  | 2 (1.00%)  | 0.931* | 1.07  | 0.229–5.004 |
| No               | 157 (79.70%) | 14 (7.10%) |       |      |         |
| **Ageusia**      |        |       |         |      |         |
| Yes              | 15 (7.60%)  | 2 (1.00%)  | 0.565* | 0.633 | 0.131–3.050 |
| No               | 166 (84.30%) | 14 (7.10%) |       |      |         |

*Chi-square.
physical examination, chest auscultation, was difficult to perform using the drive-thru method.

4. Discussion

4.1. Patient Characteristics. The degrees of mild, moderate, and severe COVID-19 are distinguished by the presence of shortness-of-breath symptoms and desaturation, which indicate pneumonia in the patient. [10] A study by Kim et al. of young COVID-19 patients showed that mild or asymptomatic disease was associated with more stable manifestations. In contrast, patients with symptoms had a greater risk of pneumonia or deteriorating computerized tomography (CT) results. [11] This was supported by Shi et al., who

| Table 4: Laboratory results and outcomes of COVID-19 self-isolation patients. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Outcome         | p value         | OR              | CI              |
| CRP            |                 |                 |                 |                 |
| Normal         | Better          | 69 (35.60%)     | 0.362 *         | 1.752           | 0.528–5.632     |
|                | Worse           | 4 (2.10%)       |                 |                 |                 |
| Increasing     |                 | 110 (56.70%)    |                 |                 |                 |
|                |                 | 11 (5.70%)      |                 |                 |                 |
| SGPT           |                 |                 |                 |                 |
| Normal         | Better          | 148 (76.30%)    | 0.032 *         | 3.183           | 1.056–9.525     |
|                | Worse           | 9 (4.60%)       |                 |                 |                 |
| Increasing     |                 | 31 (16.00%)     |                 |                 |                 |
|                |                 | 6 (3.10%)       |                 |                 |                 |
| ESR            |                 |                 |                 |                 |
| Normal         | Better          | 51 (26.20%)     | 0.21 *          | 2.57            | 0.560–11.792    |
|                | Worse           | 2 (1.00%)       |                 |                 |                 |
| Increasing     |                 | 129 (66.20%)    |                 |                 |                 |
|                |                 | 13 (6.70%)      |                 |                 |                 |
| Hb             |                 |                 |                 |                 |
| Normal         | Better          | 169 (87.10%)    | 0.232 *         | 2.6             | 0.515–13.133    |
|                | Worse           | 13 (6.70%)      |                 |                 |                 |
| Anaemia        |                 | 10 (5.20%)      |                 |                 |                 |
|                |                 | 2 (1.00%)       |                 |                 |                 |
| Haematocrit    |                 |                 |                 |                 |
| Normal         | Better          | 164 (84.50%)    | 0.817 *         | 0.781           | 0.096–6.355     |
|                | Worse           | 14 (7.20%)      |                 |                 |                 |
| Increasing     |                 | 15 (7.70%)      |                 |                 |                 |
|                |                 | 1 (0.50%)       |                 |                 |                 |
| NLR            |                 |                 |                 |                 |
| Normal         | Better          | 151 (77.80%)    | 0.269 *         | 1.961           | 0.583–6.598     |
|                | Worse           | 11 (5.70%)      |                 |                 |                 |
| Increasing     |                 | 28 (14.40%)     |                 |                 |                 |
|                |                 | 4 (2.10%)       |                 |                 |                 |

CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; ALT: Alanine aminotransferase; Hb: Hemoglobin; NLR: Neutrophil-lymphocyte ratio. * Chi-square.

| Table 5: Radiology results and outcomes of self-isolated COVID-19 patients. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | Outcome         | p value         | OR              | CI              |
| Chest X-ray     |                 |                 |                 |                 |
| Normal          | Better          | 63 (32.60%)     | 0.083 *         | 3.561           | 0.779–16.282    |
| Abnormalities   | Worse           | 2 (1.00%)       |                 |                 |                 |
|                |                 | 115 (59.60%)    |                 |                 |                 |
|                |                 | 13 (6.70%)      |                 |                 |                 |

* Chi-square.

| Table 6: Physical examinations and outcomes of COVID-19 self-isolation patients. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | Outcome         | p value         | OR              | CI              |
| Temperature     |                 |                 |                 |                 |
| Normal          | Better          | 138 (83.60%)    | 0.868           | 0.836           | 0.101–6.935     |
| Fever           | Worse           | 11 (6.70%)      | 1 (0.60%)       |                 |                 |
| Blood pressure  |                 |                 |                 |                 |
| Normal          | Better          | 101 (58.40%)    | 0.259           | 0.474           | 0.127–1.772     |
| Hypertension    | Worse           | 58 (33.50%)     | 11 (6.40%)      |                 |                 |
|                |                 | 3 (1.70%)       |                 |                 |                 |
| Pulse           |                 |                 |                 |                 |
| Normal          | Better          | 120 (67.80%)    | 0.28            | 0.441           | 0.245–1.934     |
| Tachycardia     | Worse           | 42 (23.70%)     | 13 (7.30%)      |                 |                 |
|                |                 | 2 (1.10%)       |                 |                 |                 |
| Saturation      |                 |                 |                 |                 |
| Normal          | Better          | 35 (18.00%)     | 0.218           | 3.403           | 0.433–26.754    |
| Hypoxia         | Worse           | 144 (74.20%)    | 1 (0.50%)       |                 |                 |
|                |                 | 14 (7.20%)      |                 |                 |                 |

* Chi-square.
reported a significant difference between patients with and without pneumonia in terms of improvement rates. [12] Both studies aligned with the current study, where patients with mild or asymptomatic COVID-19 had a 6.5-fold higher possibility of improved outcomes compared to patients with moderate and severe symptoms (p < 0.001).

The proportion of COVID-19 patients with secondary bacterial coinfections was 6.9%, based on the study by Langford et al. [13] Chedid et al. also reported that the average duration of secondary infections was 17 days in the non-survivor group and 14 days in the survivor group. [14] Therefore, Sieswerda et al. recommended empiric antibiotics for COVID-19 patients who were treated and had undergone bacterial culture. [15] In the current study, the use of antibiotics was significantly associated with unimproved patient outcomes. This is in contrast with the function of antibiotics, which helped overcome the secondary infections in COVID-19. The possibility is that in the current study, antibiotics were administered more often to patients with moderate-to-severe COVID-19 symptoms, showing a significant relationship with deterioration.

However, in a study conducted by Tanioka et al., the use of penicillin antibiotics was positively associated with mortality in COVID-19 patients. In contrast, other antibiotics such as cephalosporins, macrolides, and quinolones prevented mortality, although not significantly. [16] Thus, it cannot be ruled out that some antibiotics increase the likelihood of adverse outcomes in COVID-19 patients.

4.2. Clinical Manifestations. This study found that shortness of breath was a vital predictor of outcomes in COVID-19 patients, who were categorized based on severity, starting from improvement to death. [4, 5] The findings aligned with those of a systematic review and meta-analysis conducted by Shi et al., in which shortness of breath had a positive relationship with mortality outcomes in COVID-19 patients, while other significant symptoms did not demonstrate any significant associations. [12] Yang et al. also reported a significant association between dyspnea and mortality risk (odds ratio (OR): 4.52, 95% CI: 3.15–6.48, p < 0.001). [17] This was in line with the findings of the current study, in which patients who did not have shortness of breath as the major symptom had a reduced rate of deterioration, including lower mortality, than patients with shortness of breath.

In this study, fever, cough, headache, nausea, and vomiting showed no significant relationship with COVID-19 outcomes. This result was supported by a study conducted by Yang et al. Another symptom of COVID-19, fatigue, showed a significant association in their study (OR: 4.52, 95% CI: 3.15–6.48, p < 0.001), while this study found no significant association. [17]

4.3. Physical Examination. In the supervision of COVID-19 self-isolation patients, an initial physical examination was performed to determine the patient’s primary condition and degree of illness. The tests included blood pressure, temperature, oxygen saturation, pulse rate, and respiratory rate. Oxygen saturation was found in all physical examinations to significantly predict the outcome of patients undergoing COVID-19 self-isolation. Based on studies by Mejia et al. and Xie et al., saturation below 90% or desaturation strongly predicted mortality in COVID-19 patients. [18, 19] Although no studies have revealed that normal oxygen saturation is a determinant of a good prognosis in COVID-19 patients, low oxygen saturation is closely related to deterioration. This study found that patients with normal oxygen saturation could achieve a 3.4-fold higher improvement in outcomes compared to hypoxemic patients. A larger number of samples is needed to obtain statistically significant results. [10, 11].

4.4. Radiological Examination. Thoracic radiological examination is usually mandatory in COVID-19 patients where pulmonary consolidation that leads to pneumonia can be found. Cozzi et al. divided chest radiology findings based on the zone of consolidation into peripheral, lower, unilateral, and bilateral zones. [20] The study also divided the severity of the thoracic radiology findings based on the zoning system, which included only one lobe, more than one lobe, and bilateral consolidation. In their study, chest radiography had a sensitivity of 68.1% and was related to the risk of ICU admission or outcomes in COVID-19 patients. [20] Mushtaq et al. and Toussie et al. employed a scoring system to determine the severity of chest radiograph findings. Both studies showed that the severity of the initial thoracic findings was a significant determinant of outcomes among patients with COVID-19. [21, 22] The current study found that, compared to those with abnormal radiographs, patients with normal thoracic radiographs had a 3.5-fold higher chance of improved COVID-19 outcomes. The less significant result noted in this study was possibly due to the fact that radiological abnormalities were not divided more precisely. In contrast, the more severe the radiological abnormalities, the worse the prognosis.

4.5. Laboratory and Outcome Predictors. This study found no significant association between the outcomes of COVID-19 patients and CRP level. This result differed from those of Ahnach et al. and Luo et al., who found that CRP was an independent risk factor for COVID-19. [23,24] Luo et al. also showed that CRP level had a good sensitivity of 90.5% and specificity of 77.6%. [24] Although the current study did not find a significant association, the proportion of patients with elevated CRP levels was relatively high (62%). This result supports the findings of Chen et al. and Zhang et al., who reported that elevated CRP levels occurred in 93% and 91% of patients, respectively. [25, 26].

A study by Leulseged et al. showed no significant association between COVID-19 severity and hematocrit levels. [27] Their results were in line with that of our study, which found no significant association between these two parameters.

Some studies have found that NLR is a predictor of COVID-19 outcomes. Yang et al. concluded that NLR was an independent factor in COVID-19 outcome (HR 2.46, 95% CI: 1.98–4.57). [28] A study by Lagunas and Rangel also
found a significant association between these variables. [29] The current study showed different results, as only 12.5% of patients with an elevated NLR had poor outcomes.

This study found that ALT levels determined the outcome in COVID-19 patients. This is due to impaired liver function in COVID-19 patients. The relative risk for abnormal ALT levels was also higher in patients with severe COVID-19. [30] High liver enzyme levels were also found in COVID-19 patients with a significantly normal liver enzyme baseline in the study by Gholizadeh et al. [31] These two studies suggested that an increase in ALT levels was indirectly associated with COVID-19, especially in the more severe disease. Few studies have directly reported the association between elevated liver enzymes and COVID-19 outcomes or severity. However, the study revealed that lower ALT liver enzyme levels significantly affected the outcomes in COVID-19 patients on self-isolation. Further research is needed to determine the pathophysiology and the mechanism of liver damage in patients with COVID-19, which causes high levels of these liver enzymes. [11–13].

5. Conclusion

A major COVID-19 symptom, namely shortness of breath, significantly influenced the outcome of COVID-19 patients on self-isolation. Routine serum ALT assessment is recommended in these patients because ALT is a significant predictor of COVID-19 outcomes. The study strongly suggests that if a patient experienced shortness of breath, self-isolation should not be performed. Since there was a high chance of a worse outcome, our findings should improve the quality of service and monitoring of COVID-19 self-isolation patients to provide better results. This study was limited by the small number of samples compared to the total number of patients nationally and by the narrow time interval of data collection.

Data Availability

The datasets generated and/or analyzed during the current study are not publicly available due to patients’ privacy concerns but are available from the corresponding author on reasonable request.

Ethical Approval

The Ethics Committee approved this research of Universitas Indonesia Hospital, approval number S-009/KETLIT/RSUI/II/2022 with protocol number 2021-09-098. This research also followed the Declaration of Helsinki guidelines.

Consent

The Ethics Committee of Universitas Indonesia Hospital granted a waiver of informed consent due to retrospective data collection.

Conflicts of Interest

The authors declare that there are no conflicts of interest and are alone responsible for the article’s content and writing.

Authors’ Contributions

Research data were collected by RH, MAP, ASA, ZD, and APM, and AG. RH, ZD, and APM wrote the draft article. RH provided critical insight into the process of this and reviewed the final version of this manuscript. All the authors read and agreed to the final manuscript.

References

[1] Handling Task Force of COVID-19, “Distribution data of COVID-19 in Indonesia,” 2021, https://covid19.go.id/.
[2] Minister of Health of The Republic of Indonesia, “Weekly Overview of COVID-19 13th Edition,” 2021, https://www.kemkes.go.id/downloads/resources/download/laporan-mingguan-covid-Laporan-Mingguan-Penanganan-Covid-19-18-Okt-2021.
[3] O. Dyer, “Covid-19: Indonesia becomes Asia’s new pandemic epicentre as delta variant spreads,” BMJ, vol. 374, 2021.
[4] “Minister of Health of the Republic of Indonesia. COVID-19,” 2021, https://infeksiemerging.kemkes.go.id/.
[5] Information Communication and Statistics Office of Jakarta Province, “Monitoring data of COVID-19,” 2021, https://corona.jakarta.go.id/id.
[6] The Minister of Health of The Republic of Indonesia, “Decree of the minister of health of the republic of indonesian number Hk.01.07/Menkes/413/2020,” Concerning Prevention and Control Guidelines of Coronavirus Disease 2019, 2020.
[7] The Minister of Health of The Republic of Indonesia, “Decree of the minister of health of the republic of indonesian number hk.01.07/menkes/5671/2021,” Concerning Clinical Treatment Management of Virus Disease 2019 (COVID-19) at Healthcare Facilities, 2021.
[8] The Minister of Health of The Republic of Indonesia, “Decree of the minister of health of the republic of indonesian number Hk.01.07/Menkes/328/2020,” Concerning Prevention and Control Guide Coronavirus Disease 2019 (COVID-19) in the Office and Industrial Workplace in Supporting Business Continuity in a Pandemic Situation, 2020.
[9] Ministry of Health Singapore, “Updates on local situation and maintaining the stabilisation measures,” 2021, https://www.moh.gov.sg/news-highlights/details/updates-on-local-situation-and-maintaining-the-stabilisation-measures.
[10] The Minister of Health of The Republic of Indonesia, “Decree of the minister of health of the republic of indonesian number HK.01.07/Menkes/4641/2021,” Concerning the Guidelines for the Implementation of Inspection, Tracking, Quarantine, and Isolation in the Framework of Accelerating Prevention and Control Coronavirus Disease 2019, 2021.
[11] S. R. Kim, S. H. Nam, and Y. R. Kim, “Risk factors on the progression to clinical outcomes of COVID-19 patients in South Korea: using national data,” International Journal of Environmental Research and Public Health, vol. 17, no. 23, pp. 8847–8849, 2020.
[12] L. Shi, Y. Wang, Y. Wang, G. Duan, and H. Yang, “Dyspnea rather than fever is a risk factor for predicting mortality in...
patients with COVID-19," *Journal of Infection*, vol. 81, no. 4, pp. 647–679, 2020.

[13] B. J. Langford, M. So, S. Raybardhan et al., "Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis," *Clinical Microbiology and Infections*, vol. 26, no. 12, pp. 1622–1629, 2020.

[14] M. Chedid, R. Waked, E. Haddad, N. Chetata, G. Saliba, and J. Choucair, "Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy," *Journal of Infection and Public Health*, vol. 14, no. 5, pp. 570–576, 2021.

[15] E. Sieswerda, M. G. J. de Boer, M. M. J. Bonten et al., "Recommendations for antibacterial therapy in adults with COVID-19-an evidence based guideline," *Clinical Microbiology and Infections*, vol. 27, no. 1, pp. 61–66, 2021.

[16] H. Tanioka and S. Tanioka, "Risks and benefits of antibiotics vs. COVID-19 morbidity and mortality," *medRxiv*. 2020.

[17] L. I. Yang, J. Jin, W. Luo, Y. Gan, B. Chen, and W. Li, "Risk factors for predicting mortality of covid-19 patients: a systematic review and meta-analysis," *PLoS One*, vol. 15, no. 11, Article ID e0243124, 2020.

[18] F. Mejía, C. Medina, E. Cornejo et al., "Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru," *PLoS One*, vol. 15, no. 12, Article ID e0244171, 2020.

[19] J. Xie, N. Covassin, Z. Fan et al., "Association between hypoxemia and mortality in patients with COVID-19," *Mayo Clinic Proceedings*, vol. 95, no. 6, pp. 1138–1147, 2020.

[20] D. Cozzi, M. Albanesi, E. Cavigli et al., "Chest X-ray in new Coronavirus Disease 2019 (COVID-19) infection: findings and correlation with clinical outcome," *La Radiologia Medica*, vol. 125, no. 8, pp. 730–737, 2020.

[21] J. Mushtaq, R. Pennella, S. Lavalle et al., "Initial chest radiographs and artificial intelligence (AI) predict clinical outcomes in COVID-19 patients: analysis of 697 Italian patients," *European Radiology*, vol. 31, no. 3, pp. 1770–1779, 2021.

[22] D. Toussie, N. Voutsinas, M. Finkelstein et al., "Clinical and chest radiography features determine patient outcomes in young and middle-aged adults with COVID-19," *Radiology*, vol. 297, no. 1, pp. E197–E206, 2020.

[23] M. Ahnach, S. Zbiri, S. Nejjar, F. Ousti, and C. Elkettani, "C-reactive protein as an early predictor of COVID-19 severity," *Journal of Medical Biochemistry*, vol. 39, no. 4, pp. 500–507, 2020.

[24] X. Luo, W. Zhou, X. Yan et al., "Prognostic value of C-reactive protein in patients with coronavirus 2019," *Clinical Infectious Diseases*, vol. 71, no. 16, pp. 2174–2179, 2020.

[25] L. Chen, H. G. Liu, W. Liu et al., "Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia," *Zhonghua Jie He Huxi Zazhi*, vol. 43, no. 0, p. E005, 2020.

[26] J. J. Zhang, X. Dong, Y. Cao et al., "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China," *Allergy*, vol. 75, no. 7, pp. 1730–1741, 2020.

[27] T. W. Leulseged, I. S. Hassen, B. T. Ayele et al., "Laboratory biomarkers of COVID-19 disease severity and outcome: findings from a developing country," *PLoS One*, vol. 16, no. 3, Article ID e0246087, 2021.

[28] A. P. Yang, J. ping Liu, W. q Tao, and H. m Li, "The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients," *International Immunopharmacology*, vol. 84, Article ID 106504, 2020.

[29] F. A. Lagunas-Rangel, "Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis," *Journal of Medical Virology*, vol. 92, no. 10, pp. 1733-1734, 2020.

[30] M. P. Kumar, S. Mishra, D. K. Jha et al., "Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis," *Hepatol Int*, vol. 14, no. 5, pp. 711–722, 2020.

[31] R. Safari, P. Gholidazadeh, P. Marofi et al., "Alteration of liver biomarkers in patients with SARS-CoV-2 (COVID-19)," *Journal of Inflammation Research*, vol. 13, pp. 285–292, 2020.